Status:
COMPLETED
n-3 Fatty Acid Infusion and Type 2 Diabetes
Lead Sponsor:
St. Olavs Hospital
Collaborating Sponsors:
Norwegian University of Science and Technology
Norwegian Foundation for Health and Rehabilitation
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
30-75 years
Phase:
NA
Brief Summary
The purpose of this experimental study is to investigate whether an acute lipid infusion added marine n-3 fatty acids produces effects on insulin sensitivity in subjects with type 2 diabetes, when com...
Detailed Description
Evidence indicates that n-3 fatty acids exert several beneficial effects. However, the effects of marine n-3 fatty acids on intermediary metabolism have not been completely elucidated. In a previous s...
Eligibility Criteria
Inclusion
- Type 2 diabetes defined by clinical criteria and by absence of antibodies to glutamic acid decarboxylase.
- HbA1c 5,5 - 8,5 %
- Blood pressure ≤ 170 mm Hg systolic and/or ≤ 105 mm Hg diastolic
Exclusion
- insulin treatment
- hypertriglyceridemia (\> 2,1 mmol/l TG)
- proliferative retinopathy, renal insufficiency (Se-Creatinine \> 150 μmol/l)
- alcoholism, congestive heart failure or other serious diseases affecting the possibility of the subject to participate
- supplement with fish oil or marine n-3 fatty acids during the last 6 months before baseline
- Dicumarol treatment
- allergy to soya, fish or egg
- pregnancy or lactation
- smoking
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT00829569
Start Date
January 1 2004
End Date
October 1 2008
Last Update
November 4 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Medicine, Division of Endocrinology, St. Olavs Hospital
Trondheim, Norway, N-7006